KURA ONCOLOGY, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $23.09M.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $60.92M.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $324.05M, a 1620170.00% increase year-over-year.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $0.00.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2024 was $23.09M, a 62.10% decline from fiscal 2023.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2023 was $60.92M, a 146.43% increase from fiscal 2022.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2022 was $24.72M.
- KURA ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2020 was $458.98M, a 324.47% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $23.09M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $23.09M 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $60.92M 10-K · filed 2026-03-05 | |
| 2023-06-30 | $60.92M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $24.72M 10-K · filed 2025-02-28 | |
| 2020-12-31 | $324.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $458.98M 10-K · filed 2023-02-23 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $134.92M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $108.13M 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | |
| 2019-06-30 | $108.11M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $131.90M 10-K · filed 2021-02-24 |
| 2018-09-30 | $74.52M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | |
| 2018-03-31 | $57.38M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $53.67M 10-K · filed 2020-02-25 | |
| 2015-12-31 | $97.87M 10-K · filed 2017-03-14 | |
| 2007-12-31 | $50.00K 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |